


Small bug killers claim the lives of a million people every year, threatening more than 50% of the world's population

# Small bite, big threat

Common vectors like



can spread serious diseases such as:

- Malaria
- Dengue
- Yellow fever
- Japanese encephalitis
- Lymphatic filariasis (elephantiasis)
- Leishmaniasis
- Chagas disease
- Human African trypanosomiasis (sleeping sickness)
- Onchocerciasis (river blindness)
- Schistosomiasis

## Available medicines and vaccines

- Safe, affordable and highly effective vaccines are available to prevent yellow fever and Japanese encephalitis.
- Artemisinin-based combination therapy (ACT) is the best available treatment to treat malaria. Thanks to a successful partnership with MMV, a dispersible version is now available for children.
- An annual dose of ivermectin and albendazole can treat efficiently lymphatic filariasis and onchocerciasis.
- Praziquantel is the most effective treatment for schistosomiasis: it is safe, easily administered as a single dose and well tolerated.

10 programs to improve access to malaria treatments.

Donations of 10 billion treatments over 10 years (from 2011 to 2020) to help eliminate or control vector-borne diseases.



Doing our part: Pharma's 360-degree efforts to beat the bugs

## Partnerships to boost R&D

115 R&D projects in the pipeline targeting vector-borne diseases. 4 research centers solely dedicated to these diseases. Partnerships to boost R&D to develop new or improved cures for unmet medical needs:

- 39 R&D projects for malaria
- 9 for dengue
- 10 for lymphatic filariasis
- 16 for leishmaniasis
- 17 for chagas
- 9 for Human African trypanosomiasis
- 10 for onchocerciasis
- 5 for schistosomiasis

2 promising vaccines are currently being assessed in phase III trials for malaria and dengue.

Innovative collaborations to facilitate access to:

- Intellectual property
- Compound libraries
- Technical expertise
- Know-how and data
- Regulatory assistance

Our partners include WHO/TDR, WIPO, BVGH, GHIT, DNDI, MMV, MVI, Farmanguinhos Fiocruz, Swiss Tropical and Public Health Institute, Liverpool School of Tropical Medicine, Harvard School of Public Health, and many other product development partnerships (PDPs) and universities.

## Capacity-building efforts

We are working with partners to:

- Increase availability of existing treatments and vaccines.
- Strengthen health systems by equipping hospitals and dispensaries and providing essential medicines.
- Train healthcare professionals to properly deliver treatments.
- Implement mHealth programs to improve early diagnosis, adherence to treatments and reduce stock-outs of medicines.
- Raise awareness of diseases and roll out prevention programs.
- Support provision of safe water, sanitation and hygiene programs.
- Train researchers to conduct high quality R&D in disease endemic countries.
- Advocate for a science-based regulatory framework to facilitate access to new treatments.
- Provide research publications aimed at improving healthcare policy and practice.



For more information visit [www.ifpma.org](http://www.ifpma.org)